Cancer drug data and two separate Mayo Clinic-linked deals drove the biggest moves this week. Investors paid up for clearer routes to hospital rollouts, while one digital screening name fell hard after early gains evaporated.
- Amplia Therapeutics (ASX:ATX) surged on pancreatic cancer results, but the move cooled after a sharp reopen
- Echo IQ (ASX:EIQ) and 4DMedical (ASX:4DX) jumped after Mayo Clinic-linked adoption and distribution wins
- Lumos Diagnostics (ASX:LDX) landed a US waiver that lets FebriDx be used in far more clinics and pharmacies
- Cyclopharm (ASX:CYC) added more US hospital sites, which matters because Technegas pays again via consumables
- BlinkLab (ASX:BB1) slid as selling continued after a negative gap, even with trial and Morocco program news
The week’s biggest moves came from three names investors treated as near-term “proof points”. Amplia Therapeutics (ASX:ATX) rocketed 117.78% after reporting complete responses and longer survival in its ACCENT pancreatic cancer trial. Echo IQ (ASX:EIQ) rose 46.88% after expanding its Mayo Clinic agreement to distribute its heart failure software once the US regulator clears it. 4DMedical (ASX:4DX) climbed 46.05% on a double hit: a Mayo Clinic deployment of CT:VQ™ and a separate update confirming a European approval plus fresh expansion funding.
Hospital “yes” votes moved imaging stocks
Mayo Clinic’s 90‑day deployment of 4DMedical’s CT:VQ™ mattered because it is a real-world test inside one of the most watched US hospital brands. Investors care because big hospitals can influence others, and they buy at scale. CT:VQ™ also avoids radioisotopes and contrast agents. In plain terms, that can make the scan easier to run and safer for more patients. Cyclopharm (ASX:CYC) added to the same theme, rising 4.17% after a multi-site deal with Northwestern Medicine covering seven sites. That followed its earlier 11‑site University of Pennsylvania Health System deal. The attraction for investors is simple: once Technegas is installed, the company can earn repeat revenue from consumables and service, not just a one-off sale.Diagnostics: US access expanded, but the next hurdle is selling
Lumos Diagnostics (ASX:LDX) slipped -1.92% despite winning a key US FDA clearance plus a CLIA waiver for FebriDx®. A CLIA waiver matters because it allows use in far more places outside big labs, such as clinics and urgent care. The company says that lifts the reachable US patient pool to about 80 million a year and opens more than 300,000 US healthcare locations. Nexsen (ASX:NXN) gained 9.38% as it tightened its plan for StrepSure®, a rapid Group B Strep test used in pregnancy care. The company has now completed a US FDA pre-submission meeting and is targeting a 510(k) submission in Q4 2026. Investors tend to respond when the regulator has already reviewed the study plan, because it lowers the chance of an expensive re-do later. Cleo Diagnostics (ASX:COV) rose 5.21% after expanding its ovarian cancer marker panel from five to eight and flagging an imminent manufacturing deal. More markers can mean a steadier test, but the risk is that bigger panels can also complicate validation and manufacturing.Software and data deals: fewer promises, more contracts
Enlitic (ASX:ENL) jumped 33.33% after a US$1.5 million contract to migrate 71 million clinical files for Penn Medicine Doylestown Health. This is not “AI hype” revenue. It is paid work to move large volumes of hospital data into a modern archive, starting in Q2 2026. Echo IQ’s (ASX:EIQ) rally also sat in this bucket. The expanded agreement with Mayo Clinic includes improved commercial terms and an automatic six‑year extension once FDA clearance arrives. The plain-English risk is timing: until the regulator signs off, hospitals cannot buy it as a routine clinical tool. PainChek (ASX:PCK) added 30.00% after reporting 4,000 new UK aged care licences and 9% quarter-on-quarter growth, adding about A$230,000 in annual recurring revenue. The key question is whether the same product can win at scale in North America, where procurement and reimbursement rules differ.Where the selling showed up
BlinkLab (ASX:BB1) fell -12.35% even though it started a pivotal US FDA validation study for its autism diagnostic aid and also announced selection for Morocco’s national early screening program. The trading action suggests early gains evaporated and more sellers kept pushing the price down after it reopened lower. For beginners, this can happen when investors worry about how long trials take and how much cash is needed before meaningful sales arrive. Elsewhere, EBR Systems (ASX:EBR) dropped -9.86% after executing a one-for-ten reverse stock split. A reverse split does not change the business. It reduces the share count and lifts the share price by the same factor, but it can still unsettle short-term traders. Firebrick Pharma (ASX:FRE) eased -8.47%-11.21%Capital and supply: scaling costs money 4DMedical’s (ASX:4DX) separate update combined a CE Mark (which allows sales across the European Union) with an $83 million private placement at $5.90 a share. Investors liked the speed of expansion plans and the stated pro-forma cash balance of $289 million (December 2025). The trade-off is dilution: more shares on issue can reduce each existing share’s slice of future profits. Clarity Pharmaceuticals (ASX:CU6) fell -4.39%0.00%Bottom Line?Near-term attention sits on dated catalysts: Radiopharm Theranostics (ASX:RAD) expects final Phase 2b RAD 101 data by June, while Amplia Therapeutics (ASX:ATX) plans to present narmafotinib data at AACR 2026 in San Diego. Over the next 6, 12 months, deal flow inside hospital networks will matter as much as lab results, with Mayo Clinic-linked rollouts for 4DMedical (ASX:4DX) and Echo IQ (ASX:EIQ) setting the pace.
Questions in the middle?
- Will Mayo Clinic’s CT:VQ™ deployment convert into a broader purchase program, and how quickly could other US academic centres follow?
- After FebriDx® won a US CLIA waiver, what will Lumos (ASX:LDX) report first: strong placement numbers in clinics, or slower uptake due to sales and training limits?
- Can BlinkLab (ASX:BB1) finish recruitment for its pivotal study within the stated eight months, and will Morocco’s national program translate into repeatable revenue elsewhere?